ונופר ישראל - עברית - Ministry of Health

ונופר

cts ltd - ferrous as iron iii hydroxide sucrose complex - תמיסה להזרקה - ferrous as iron iii hydroxide sucrose complex 100 mg / 5 ml - iron-sorbitol-citric acid complex - iron-sorbitol-citric acid complex - severe iron deficiency only when oral administration has been found impossible. in cases of gastro-intestinal malobsorption which rules out oral therapy, patients on dialysis treated with erythropoietin.

רופילק 300 ישראל - עברית - Ministry of Health

רופילק 300

csl behring ltd., israel - anti-d immunoglobulins - תמיסה להזרקה - anti-d immunoglobulins 150 mcg/ml - anti-d (rh) immunoglobulin - anti-d (rh) immunoglobulin - prophylaxis of rh (d) immunisation in rh (d)-negative women: anti-d immune globulin is administered for the prevention of rh (d) immunization if it has been demonstrated or if it is suspected that fetal erythrocytes have entered the circulation of the mother. treatment is not necessary when it is assured that the child or the father are rh (d)- negative. criteria for a rhesus-incompatible pregnancy and the administration of anti-d immune globulin are : a) the mother is rh (d) -negative b) the child is either rh (d)-positive rh (d)weak - positive or its rhesus type is not known. routine antepartum prophylaxis : to prevent rh (d) immunisation due to spontaneous fetomaternal haemorrhage (fmh) during the last trimester of pregnancy. postpartum prophylaxis to prevent rh (d) immunisation of the rh (d)-negative mother following delivery of a rh (d)-positive child. complications of pregnancy: interventions during pregnancy such as invasive prenatal diagnosis (e.g. amniocentesis chorionic villus sampling fetal blood s

פרינג'קט ישראל - עברית - Ministry of Health

פרינג'קט

cts ltd - ferric carboxymaltose - תמיסה להזרקה\אינפוזיה - ferric carboxymaltose 1800 mg/vial - ferinject is indicated for treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. the diagnosis must be based on laboratory tests.

פרינג'קט ישראל - עברית - Ministry of Health

פרינג'קט

cts ltd - ferric carboxymaltose - תמיסה להזרקה\אינפוזיה - ferric carboxymaltose 1800 mg/vial

פרינג'קט ישראל - עברית - Ministry of Health

פרינג'קט

cts ltd - ferric carboxymaltose - תמיסה להזרקה\אינפוזיה - ferric carboxymaltose 1800 mg/vial

פרינג'קט ישראל - עברית - Ministry of Health

פרינג'קט

cts ltd - ferric carboxymaltose - תמיסה להזרקה\אינפוזיה - ferric carboxymaltose 1800 mg/vial

פרינמיה ישראל - עברית - Ministry of Health

פרינמיה

a.l. medi-market ltd. - iron iii as iron iii hydroxide sucrose complex - iron iii as iron iii hydroxide sucrose complex 20 mg / 1 ml - saccharated iron oxide

קסמיאול ישראל - עברית - Ministry of Health

קסמיאול

dexcel ltd, israel - betamethasone as dipropionate; calcipotriol as hydrate - ג'ל - betamethasone as dipropionate 0.5 mg / 1 g; calcipotriol as hydrate 50 mcg / 1 g - betamethasone - betamethasone - topical treatment of psoriasis vulgaris on the scalp and topical treatment of mild to moderate “non-scalp” plaque psoriasis vulgaris in adults 18 years of age and older.

היקמטין 0.25 מג ישראל - עברית - Ministry of Health

היקמטין 0.25 מג

novartis israel ltd - topotecan as hydrochloride - קפסולות ג'לטין קשיחות - topotecan as hydrochloride 0.25 mg - topotecan - topotecan - indicated for the treatment of patients with relapsed small cell lung cancer (sclc) for whom re-treatment with the first-line regimen is not considered appropriate.

ארומזין ישראל - עברית - Ministry of Health

ארומזין

pfizer pfe pharmaceuticals israel ltd - exemestane - טבליות מצופות - exemestane 25 mg - exemestane - exemestane - aromasin is indicated for the treatment of advanced breast cancer (abc) in women with natural or induced postmenopausal status whose disease has progressed following anti-oestrogen therapy alone. aromasin is also indicated for the treatment of postmenopausal women with abc whose disease has progressed following multiple hormonal therapies. aromasin is indicated for the adjuvant treatment of postmenopausal women with oestrogen receptor positive invasive early breas cancer following 2-3 years of initial adjuvant tamoxifen therapy.